<code id='36FAE02066'></code><style id='36FAE02066'></style>
    • <acronym id='36FAE02066'></acronym>
      <center id='36FAE02066'><center id='36FAE02066'><tfoot id='36FAE02066'></tfoot></center><abbr id='36FAE02066'><dir id='36FAE02066'><tfoot id='36FAE02066'></tfoot><noframes id='36FAE02066'>

    • <optgroup id='36FAE02066'><strike id='36FAE02066'><sup id='36FAE02066'></sup></strike><code id='36FAE02066'></code></optgroup>
        1. <b id='36FAE02066'><label id='36FAE02066'><select id='36FAE02066'><dt id='36FAE02066'><span id='36FAE02066'></span></dt></select></label></b><u id='36FAE02066'></u>
          <i id='36FAE02066'><strike id='36FAE02066'><tt id='36FAE02066'><pre id='36FAE02066'></pre></tt></strike></i>

          
          WSS
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge